galcanezumab Emgality
Selected indexed studies
- ** (, 2022) [PMID:37906661]
- Galcanezumab. (, 2012) [PMID:31643470]
- Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. (Neurology, 2018) [PMID:30446596]
_Worker-drafted node — pending editorial review._
Connections
galcanezumab Emgality is a side effect of
Sources
- Migraine overview and summary of current and emerging treatment options. (2019) pubmed
- Galcanezumab. (2012) pubmed
- Galcanezumab. (2006) pubmed
- Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. (2018) pubmed
- Galcanezumab: First Global Approval. (2018) pubmed
- Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial. (2024) pubmed
- A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study. (2024) pubmed
- PMID:37906661 (2022) pubmed
- Galcanezumab (Emgality) for Migraine and Cluster Headaches. (2020) pubmed
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. (2020) pubmed